Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $122.08.
Several brokerages recently issued reports on AXSM. Morgan Stanley raised Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $90.00 to $115.00 in a research report on Monday, April 29th. Robert W. Baird lifted their price objective on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 7th. Truist Financial reissued a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, March 26th. Citigroup dropped their price target on shares of Axsome Therapeutics from $127.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th. Finally, Mizuho reissued a “buy” rating and set a $106.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, June 12th.
View Our Latest Research Report on Axsome Therapeutics
Insider Activity
Hedge Funds Weigh In On Axsome Therapeutics
Several large investors have recently added to or reduced their stakes in AXSM. Washington Trust Advisors Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $26,000. EntryPoint Capital LLC purchased a new position in Axsome Therapeutics during the 1st quarter worth $35,000. Russell Investments Group Ltd. grew its stake in shares of Axsome Therapeutics by 5,550.0% in the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after acquiring an additional 777 shares in the last quarter. Covestor Ltd raised its holdings in shares of Axsome Therapeutics by 54,750.0% in the first quarter. Covestor Ltd now owns 1,097 shares of the company’s stock valued at $88,000 after purchasing an additional 1,095 shares during the last quarter. Finally, Janiczek Wealth Management LLC bought a new position in shares of Axsome Therapeutics during the first quarter valued at about $97,000. Institutional investors own 81.49% of the company’s stock.
Axsome Therapeutics Stock Performance
Shares of AXSM stock opened at $80.21 on Friday. The business’s 50-day moving average price is $75.48 and its 200-day moving average price is $78.88. Axsome Therapeutics has a 12 month low of $55.02 and a 12 month high of $98.40. The company has a current ratio of 3.20, a quick ratio of 3.09 and a debt-to-equity ratio of 1.25. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of -12.57 and a beta of 1.26.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its earnings results on Monday, May 6th. The company reported ($1.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.11. The firm had revenue of $75.00 million for the quarter, compared to analyst estimates of $69.91 million. Axsome Therapeutics had a negative net margin of 118.07% and a negative return on equity of 87.17%. Equities research analysts forecast that Axsome Therapeutics will post -4.7 EPS for the current year.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
- Five stocks we like better than Axsome Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Where to Find Earnings Call Transcripts
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- Most active stocks: Dollar volume vs share volume
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.